203190-57-2

Basic information

• Product Name: 3-(allyloxy)-4-aminobenzonitrile
• Synonyms: 3-(allyloxy)-4-aminobenzonitrile
• CAS NO: 203190-57-2
• Molecular Weight: 174.202
• Mol File: 203190-57-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(allyloxy)-4-aminobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(allyloxy)-4-aminobenzonitrile(203190-57-2)
• EPA Substance Registry System: 3-(allyloxy)-4-aminobenzonitrile(203190-57-2)

Safety Data

• Hazardous Substances Data: 203190-57-2(Hazardous Substances Data)

Upstream product

• 55586-26-0 3-hydroxy-4-aminobenzonitrile 
• 106-95-6 allyl bromide 
• 18495-15-3 3-hydroxy-4-nitrobenzonitrile 
• 203190-56-1 1-allyloxy-5-cyano-2-nitrobenzene 
• 7772-99-8 stannous chloride 

Downstream Products

• 203201-41-6 2-amino-5-cyano-6-prop-1-ene-3-yl-phenol 
• 203190-59-4 N-(2-Allyloxy-4-cyanophenyl)-N'-(2-bromophenyl)-thiourea 
• 203201-42-7 2-Amino-5-cyano-6-propyl-phenol 
• 203190-60-7 N-(2-Allyloxy-4-cyanophenyl)-N'-(2-bromophenyl)-carbodiimide 
• 203201-37-0 N-(2-Allyloxy-4-cyanophenyl)-N'-(2-bromophenyl)-N-cyanoguanidine 
• 203201-29-0 N-(2-bromophenyl)-N'-(4-cyano-2-hydroxy-3-propylphenyl)-N-cyanoguanidine 

Relevant articles and documents

Discovery of 1,5-Dihydro-4 H-imidazol-4-one Derivatives as Potent, Selective Antagonists of CXC Chemokine Receptor 2

CXC chemokine receptors 1 (CXCR1) and 2 (CXCR2) have been demonstrated to have critical roles in cancer metastasis. Because they share high homology sequences, it is still unclear how to design selective CXCR1 or CXCR2 antagonists. Based on a pharmacophore model we built, compound 2 bearing a 1,5-dihydro-4H-imidazol-4-one scaffold was identified as a selective CXCR2 antagonist with a low CXCR1 antagonism preference. Further optimization and structure-activity relationship studies led to compound C5 that overcame the disadvantages of compound 2 and performed with higher selectivity. It showed excellent oral bioavailability and in vitro anticancer metastasis activity. Further dynamic simulation of the molecular protein complex showed that the amino acid residue K320 of CXCR2 contributed most to the selectivity of C5. This study provides important clues for the design of new CXCR2 selective antagonists, and C5 can be a molecular tool for investigating the difference in the biological function of CXCR1 and CXCR2.

IL-8 receptor antagonists

This invention relates to novel compounds, pharmaceutical compositions comprising these compounds and their use in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).